Objective To investigate the occurrence and risk factors of upper gastrointestinal bleeding caused by dual antiplatelet therapy. Methods The clinical data of 212 patients with coronary heart disease who received dual antiplatelet therapy in the First People's Hospital of Nankang District, Ganzhou City from September 2018 to August 2020 were retrospectively analyzed.All patients received dual antiplatelet therapy.After 1 year of treatment, the incidence of upper gastrointestinal bleeding was analyzed.Patients were divided into occurrence group and non-occurrence group according to whether upper gastrointestinal bleeding occurred or not.The clinical data of the two groups including gender, age, complicated underlying diseases, history of peptic ulcer, history of alcohol consumption, application of gastric mucosal protective agent, proton pump inhibitor and serum creatinine (Scr) level were analyzed, and the risk factors for upper gastrointestinal bleeding were analyzed. Results 212 patients with coronary heart disease were treated with dual antiplatelet therapy, and 25 patients developed upper gastrointestinal bleeding during one-year follow-up,with an incidence rate of 11.79% (25/212).The proportion of patients with peptic ulcer related history, no use of proton pump inhibitors and Scr level ＞113 μmol/L in the occurrence group were higher than those in the non-occurrence group, and the differences were statistically significant (P＜0.05).Multivariate logistic regression analysis showed that a history of peptic ulcer, no use of proton pump inhibitors and Scr level ＞113 μmol/L were independent risk factors for upper gastrointestinal bleeding induced by dual antiplatelet therapy (P＜0.05). Conclusion Dual antiplatelet therapy may lead to upper gastrointestinal bleeding, and the related risk factors should be paid more attention to in clinic.